|Other names||Tenapanor hydrochloride|
|Drug class||NHE3 inhibitors|
|Chemical and physical data|
|Molar mass||1145.04 g·mol−1|
|3D model (JSmol)|
Common side effects include diarrhea, abdominal swelling, and lightheadedness. Use in pregnancy and breastfeeding is believed to be safe. It acts by blocking the sodium-proton exchanger NHE3 there by decreasing the uptake of sodium by the intestines.
It is usually taken at a dose of 50 mg two times per day.
- "Tenapanor Monograph for Professionals". Drugs.com. Retrieved 25 September 2021.
- "Ibsrela Prices and Ibsrela Coupons - GoodRx". GoodRx. Retrieved 25 September 2021.
- "Tenapanor". SPS - Specialist Pharmacy Service. 26 May 2017. Retrieved 25 September 2021.
- "Drug Trials Snapshots: Ibsrela". U.S. Food and Drug Administration (FDA). 27 September 2019. Archived from the original on 19 November 2019. Retrieved 18 November 2019. This article incorporates text from this source, which is in the public domain.
- "New Drug Therapy Approvals 2019". U.S. Food and Drug Administration. 31 December 2019. Retrieved 15 September 2020.